Jurriaan Brouwer‐Visser

Regeneron (United States) — United States

Medicine · Health Sciences

16h-index1.1kcitations105works5.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(34), Lymphoma Diagnosis and Treatment(27), Sarcoma Diagnosis and Treatment(18), Cancer Immunotherapy and Biomarkers(14), Ovarian cancer diagnosis and treatment(13)

Publications105 total

Odronextamab plus chemotherapy in patients with previously untreated follicular lymphoma: First results from part 1 of the Phase 3 Olympia-2 study
Blood·2025Open Access
Odronextamab (Odro) plus lenalidomide (+Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): First results from part 1 (safety lead-in) of the Phase 3 OLYMPIA-5 study
Blood·2025
Phased variant circulating tumor DNA (ctDNA) tracking provides limited additional power in predicting progressive disease compared with duplex variant tracking in patients with Relapsed/Refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) treated with odronextamab
Blood·2025
Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): First Results from part 1 of the Phase 3 Olympia-3 study
Blood·2025
Efficacy and safety of long-term odronextamab treatment in patients with relapsed/refractory follicular lymphoma: 3-year follow-up from the Phase 2 ELM-2 study
Blood·2025
635 The impact of bispecific antibody CD22xCD28 on anti-tumor efficacy of odronextamab and T cell activation and function in B cell tumor models
Regular and Young Investigator Award Abstracts·2025Open Access
546 Sarilumab as a potential mitigator of ubamatamab (MUC16×CD3)-induced cytokine release syndrome (CRS) in patients with advanced ovarian cancer (OC) or endometrial cancer (EC)
Regular and Young Investigator Award Abstracts·2025Open Access
A PHASE 1/2 STUDY OF UBAMATAMAB (REGN4018) IN LOW-GRADE SEROUS OVARIAN CANCER COHORT
International Journal of Gynecological Cancer·2025
Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL
Blood Advances·2025· 1 citedOpen Access
MUC16 as a novel therapeutic target for high-grade endometrial cancer
Gynecologic Oncology·2025
IBCL-576: Long-Term Follow-Up of the Phase 2 ELM-2 Study: Efficacy and Survival Outcomes With Odronextamab in Relapsed/Refractory Follicular Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: IBCL-576 Long-Term Follow-Up of the Phase 2 ELM-2 Study: Efficacy and Survival Outcomes With Odronextamab in Relapsed/Refractory Follicular Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2025
425 | BIOMARKER ANALYSES OF THE INFLAMMATORY PROFILE AND MRD IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA VERSUS FOLLICULAR LYMPHOMA TREATED WITH ODRONEXTAMAB
Hematological Oncology·2025Open Access
242 | LONG‐TERM EFFICACY AND SURVIVAL OUTCOMES WITH ODRONEXTAMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): 2‐YEAR FOLLOW‐UP FROM THE PHASE 2 ELM‐2 STUDY
Hematological Oncology·2025Open Access
424 | LONGITUDINAL TARGETED ctDNA ANALYSIS TO ASSESS CD20 and BAFF MUTATIONS IN PATIENTS WITH RELAPSED/REFRACTORY FL OR DLBCL PROGRESSING ON ODRONEXTAMAB IN THE ELM‐2 STUDY
Hematological Oncology·2025Open Access
Long-term follow-up of the phase 2 ELM-2 study: Odronextamab for patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL).
Journal of Clinical Oncology·2025· 1 cited
Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Nature Cancer·2025Open Access
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Nature Cancer·2025· 34 citedOpen Access
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
Blood·2024· 20 citedOpen Access
Corrigendum to “Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma”
Annals of Oncology·2024· 2 cited
page 1 of 6Next →

Frequent Co-authors

Aafia Chaudhry(26), Srikanth Ambati(24), Min Zhu(23), Hesham Mohamed(23), Manjusha Namuduri(11), Gloria S. Huang(9), Dina M. Flink(8), Tae Min Kim(7), Seok‐Goo Cho(7), Vladimir Janković(7), Jingxian Cai(7), Ashish Risal(7), Benoît Tessoulin(6), David Tucker(6), Stefano Luminari(6), Michał Taszner(5), Silvana Novelli(5), Geoffrey Chong(5), Stéphanie Guidez(5), Elżbieta Iskierka‐Jazdzewska(5)